3
Announcements
Trials
Browse
Landscape
Status
Completed
4
Sponsor Class
OTHER
4
INDUSTRY
4
Study Type
Interventional
7
Observational
4
Sponsor
Conditions
Breast Neoplasms
467
Neoplasms
315
Carcinoma, Non-Small-Cell Lung
269
Prostatic Neoplasms
215
Colorectal Neoplasms
207
Lung Neoplasms
176
Multiple Myeloma
123
Melanoma
110
Carcinoma, Renal Cell
107
Ovarian Neoplasms
94
Carcinoma, Hepatocellular
78
Pancreatic Neoplasms
69
Urinary Bladder Neoplasms
65
Stomach Neoplasms
64
Neoplasm Metastasis
64
Leukemia, Lymphocytic, Chronic, B-Cell
62
Colonic Neoplasms
59
Leukemia, Myeloid, Acute
53
Uterine Cervical Neoplasms
50
Recurrence
49
Liver Neoplasms
46
Lymphoma, Follicular
45
Lymphoma
45
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
39
Esophageal Neoplasms
37
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma, Large B-Cell, Diffuse
35
Hematologic Neoplasms
35
Head and Neck Neoplasms
35
Lymphoma, Non-Hodgkin
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Observational
×
Breakthrough Pain
×
Clear all
NCT03435120
2020-03-02
CAVIDIOM
Angelini Farmacéutica
Completed
118 enrolled
NCT02836379
2018-03-05
CAVIDIOR
Angelini Farmacéutica
Completed
79 enrolled
NCT02840500
2018-03-05
CAVIDIOPAL
Angelini Farmacéutica
Completed
101 enrolled
NCT00994760
2012-09-27
GENISIS
Takeda
Completed
131 enrolled
33 charts